Immediate Impact
41 standout
Citing Papers
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
2024 Standout
Works of L. Uwer being referenced
A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| L. Uwer | 69 | 31 | 2 | 18 | 17 | 101 | |
| Lionel Uwer | 137 | 55 | 4 | 19 | 14 | 184 | |
| Miriam O’Connor | 42 | 21 | 12 | 12 | 18 | 106 | |
| Jeroen W. G. Derksen | 96 | 16 | 7 | 24 | 21 | 171 | |
| Sylvie Luce | 36 | 36 | 1 | 52 | 16 | 121 | |
| Rebecca Hoyd | 108 | 41 | 3 | 15 | 27 | 170 | |
| Leonor Vasconcelos de Matos | 77 | 28 | 2 | 6 | 21 | 114 | |
| J. Chamois | 48 | 55 | 16 | 19 | 122 | ||
| Mathieu Baconnier | 104 | 45 | 13 | 15 | 128 | ||
| Wan Qin Chong | 73 | 21 | 3 | 5 | 20 | 126 | |
| Emmanuelle Jacquet | 41 | 26 | 4 | 7 | 12 | 75 |
All Works
Loading papers...